BMY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bristol-Myers Squibb is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The business fundamentals are solid and Q1 results were positive, but the stock is technically weak, momentum is negative, and there is no Intellectia buy signal today. For an impatient investor who does not want to wait for a better entry, I would not buy here; hold and wait for a cleaner setup.
The trend is soft to bearish in the near term. MACD histogram is -0.251 and still expanding lower, which confirms negative momentum. RSI_6 at 32.81 is near oversold but not yet a strong reversal signal. Moving averages are converging, suggesting the stock is not in a strong uptrend. Price at 56.23 is sitting just above S1 support at 56.07 and below the pivot at 58.061, so it is trading in a vulnerable area. The pattern-based forecast also points to weakness over the next week and month, which reinforces a cautious stance.
["Q1 revenue rose 2.57% YoY to $11.49B.", "Q1 net income increased 9.00% YoY and EPS rose 9.17% YoY.", "Gross margin improved to 66.53%, up 1.34% YoY.", "Analysts continue to point to second-half 2026 pipeline catalysts, especially milvexian and Cobenfy.", "Recent pharma M&A activity suggests the sector remains attractive and supportive of large-cap biotech/pharma valuations."]
["MACD is negative and worsening, signaling weak momentum.", "Price is below the pivot and close to support, which is not ideal for an immediate long-term entry.", "The stock trend model implies downside over the next week and month.", "Analysts remain mixed overall, with several Neutral/Hold-type views despite higher price targets.", "The company still faces a patent cliff narrative tied to Eliquis and Opdivo over time.", "No AI Stock Picker or SwingMax buy signal is present today."]
Latest reported quarter: 2026/Q1. Financial performance was solid, with revenue up 2.57% YoY to $11.49B, net income up 9.00% YoY to $2.677B, EPS up 9.17% YoY to $1.31, and gross margin improving to 66.53%. This shows continued earnings strength and stable operating performance in the latest quarter season, but growth is still modest rather than explosive.
Analyst sentiment has improved at the margin, with several firms raising price targets recently. Citi lifted its target to $66 and kept Neutral, BofA trimmed to $67 but kept Buy, Cantor raised to $54 and stayed Neutral, UBS lifted to $70 and kept Buy, and Barclays and Piper Sandler remain bullish with Overweight/Buy-style views and higher targets. The pros view is that BMY has attractive pipeline catalysts and potential multiple expansion. The cons view is that the current rally may already reflect macro support and catalyst hopes, while legacy patent-cliff concerns still weigh on long-term visibility. Overall, Wall Street is constructive but not unanimously positive.
